Eli Lil­ly un­veils a com­plete makeover, erect­ing a neu­ro­science unit cen­tered on Alzheimer's as it uni­fies on­col­o­gy biz

The FDA ap­proval of Bio­gen’s Aduhelm for Alzheimer’s has breathed new life in­to neu­rol­o­gy units across bio­phar­ma, none more so than near­est ri­val Eli Lil­ly. Look­ing to ride that build­ing wave, Lil­ly is ready for a new look.

Lil­ly will break up its larg­er Bio-Med­i­cines busi­ness, prop­ping up new neu­ro­science and im­munol­o­gy units as part of a broad re­or­ga­ni­za­tion of the In­di­anapo­lis drug­mak­er’s pipeline cen­tered, in part, around late-stage Alzheimer’s can­di­date do­nanemab, the com­pa­ny an­nounced Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER